Charles River Laboratories (CRL) Tops Q4 EPS by 23c; Guides FY23 EPS Below Views

Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.98, $0.23 better than the analyst estimate of $2.75. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.

GUIDANCE:

Charles River Laboratories sees FY2023 EPS of $9.70-$10.90. Charles River Laboratories sees FY2023 revenue of $11.37 billion. Revenue growth, reported up 1.5-4.5%. Sees Revenue growth, organic up 4.5-7.5%.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c